India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, mitochondrial function is enhanced by 30-60 percent. “Based on our analysis of this and other previously announced compelling data, we are readying IGC-AD1 in a liquid formulation that will not cause inebriation,” Ram Mukunda, CEO of IGC, stated in the news release. “The initial commercialization will be through licensed medical cannabis dispensaries.” As noted in this morning’s update, mitochondrial dysfunction is believed to be at the apex of the Alzheimer’s pyramid, making it responsible for triggering a cascade of symptoms resulting in the devastating condition. As such, IGC-AD1’s ability to improve mitochondrial function could serve as a significant breakthrough in the treatment of Alzheimer’s, which is noted as America’s most expensive disease with its estimated annual cost of $236 billion.
To view the full press release, visit http://dtn.fm/MyB72
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
